Continuous Glucose Monitor

In this Healio Video Exclusive, Caroline T. Nguyen, MD, speaks with Sarit Polsky, MD, MPH, about the use of continuous glucose monitoring for pregnant women with gestational diabetes and type 1 diabetes.

Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated insulin delivery system, according to findings from the SECURE-T2D trial.

Sodium-glucose cotransporter 2, or SGLT2, inhibitors may be more cardioprotective for older adults, whereas glucagon-like peptide-1 receptor agonists may confer greater HbA1c reductions in that population, according to a systematic review and meta-analysis.

The use of a continuous glucose monitor during pregnancy may be more cost-effective than self-monitoring blood glucose for women with type 1 diabetes, according to a brief report published in Diabetes Technology & Therapeutics.

Hybrid closed-loop systems outperformed other types of subcutaneous insulin treatment for diabetes, but some systems were more efficient than others, according to results published in Diabetes/Metabolism Research and Reviews.

A new error grid to assess the accuracy of glucose measurements could give continuous glucose monitor manufacturers and regulatory agencies such as the FDA a better understanding of how accurate their devices are.

New guidance on GLP-1 receptor agonist use, how to tackle medication shortages and expanded continuous glucose monitoring use for type 2 diabetes are among the updates in the American Diabetes Association’s 2025 Standards of Care.

Continuous glucose monitoring can lower mortality risk in addition to improving glycemic control for people with diabetes, according to a speaker at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease.

From 1990 to 2022, diabetes prevalence rose greatly, but for the most part, treatment did not increase at all or sufficiently, especially in low- and middle-income countries, researchers reported in The Lancet.

Sotagliflozin was not recommended for approval by the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee for glucose control as an adjunct to insulin in adults with type 1 diabetes and chronic kidney disease..